LarotrectinibAcquired drug resistance and liver toxicity following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1978卷 / 1期

关键词：

D O I：

10.1007/s40278-023-47588-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：221 / 221

相关论文

共 50 条

[1] ErtapenemAcquired drug resistance following off-label use: case report
Reactions Weekly, 2022, 1909 (1) : 245 - 245
[2] RuxolitinibGrade 3 liver toxicity following off-label use: case report
Reactions Weekly, 2020, 1815 (1) : 293 - 293
[3] CrizotinibLiver toxicity following off-label use: case report
Reactions Weekly, 2015, 1551 (1) : 92 - 92
[4] HydroxychloroquineCardiac toxicity following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 374 - 374
[5] VemurafenibSkin toxicity following off-label use: case report
Reactions Weekly, 2015, 1563 (1) : 212 - 212
[6] BaclofenComa secondary to drug toxicity following an overdose and off-label use: case report
Reactions Weekly, 2023, 1983 (1) : 97 - 97
[7] AntineoplasticsTreatment failure, drug resistance and off-label use: case report
Reactions Weekly, 2022, 1931 (1) : 85 - 85
[8] Ivabradine overdoseBradycardia and drug toxicity following an off-label treatment : case report
Reactions Weekly, 2022, 1933 (1) : 256 - 256
[9] Cetuximab/encorafenibDevelopment of drug resistance and off-label use: case report
Reactions Weekly, 2022, 1894 (1) : 103 - 103
[10] Alectinib/crizotinibAcquired drug resistance and off-label use: case report
Reactions Weekly, 2021, 1856 (1) : 23 - 23

← 1 2 3 4 5 →